Patent application number | Description | Published |
20100199353 | VULNERABILITY-BASED REMEDIATION SELECTION - A machine-actionable memory comprises one or more machine-actionable records arranged according to a data structure. Such a data structure may include links that respectively map between a remediation, at least one action, and at least two vulnerabilities. A method of selecting a remediation, that is appropriate to a vulnerability which is present on a machine to be remediated, may include: providing a machine-actionable memory as mentioned above; and indexing into the memory using: a given vulnerability identifier to determine (A) at least one of a remediation mapped thereto and (B) at least one action mapped to the given vulnerability identifier; and/or a given remediation to determine at least two vulnerabilities mapped thereto. | 08-05-2010 |
20120192281 | DETERMINING TECHNOLOGY-APPROPRIATE REMEDIATION FOR VULNERABILITY - A machine-actionable memory comprises one or more machine-actionable records arranged according to a data structure. Such a data structure may include links that respectively map between: a RID field, the contents of which denote an identification (ID) of a remediation (RID); at least one TID field, the contents of which denotes an ID of at least two technologies (TIDs), respectively; and at least one ACTID field, the contents of which denotes an ID of an action (ACTID). A method, of selecting a remediation that is appropriate to a technology present on a machine to be remediated, may include: providing such a machine-actionable memory; and indexing into the memory using a given RID value and a given TID value to determine values of the at-least-one ACTID corresponding to the given RID value and appropriate to the given TID value. | 07-26-2012 |
20130333044 | VULNERABILITY-BASED REMEDIATION SELECTION - A machine-actionable memory comprises one or more machine-actionable records arranged according to a data structure. Such a data structure may include links that respectively map between a remediation, at least one action, and at least two vulnerabilities. A method of selecting a remediation, that is appropriate to a vulnerability which is present on a machine to be remediated, may include: providing a machine-actionable memory as mentioned above; and indexing into the memory using: a given vulnerability identifier to determine (A) at least one of a remediation mapped thereto and (B) at least one action mapped to the given vulnerability identifier; and/or a given remediation to determine at least two vulnerabilities mapped thereto. | 12-12-2013 |
Patent application number | Description | Published |
20090264494 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS - The present invention include providing a therapeutically effective amount of a 3-substituted indolin-2-one compositions to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such as ischemic stroke | 10-22-2009 |
20100298376 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS - The present invention provides compositions and methods of synthesizing optionally substituted 3-substituted indolin-2-ones and methods to employ the resultant compounds to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such as ischemic stroke. | 11-25-2010 |
20110144029 | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases - The present invention provides models for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can modulate such development and/or pathologies. | 06-16-2011 |
20120094991 | 1, 4-Benzoxazine Compounds and Derivatives Thereof as Therapeutic Drugs for the Treatment of Neurodegenerative Conditions - The present invention includes compositions and methods for inhibiting kinase activity to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such as ischemic stroke comprising the step of providing the subject with a therapeutically affective amount of 1,4-benzoxazine compounds and derivatives thereof. | 04-19-2012 |